Abstract:Abstract Purpose Triple-negative breast cancer (TNBC) is a highly diverse group of disease, and clinical outcome of patients with TNBC is highly variable. Due to the heterogeneity of TNBCs, there is limited molecular signature routinely used for predicting the risk of disease recurrence and benefit of adjuvant chemotherapy. Our study aims to develop and validate a RNA signature, integrating messenger RNAs (mRNAs) and long non-coding RNAs (lncRNAs) together, for TNBC patients to improve risk stratification and avoid unnecessary adjuvant therapy. Methods Using transcriptome microarrays, we analyzed 33 paired TNBC and adjacent normal breast tissues, and identified 1,644 mRNAs and 1,047 lncRNAs which were differentially expressed between tumors and normal tissues. We further determined the expression of these mRNAs and lncRNAs in an additional 134 TNBC samples using transcriptome microarrays, and confirmed their associations with patients' recurrence-free survival (RFS). Using the LASSO Cox regression model, we built an integrated mRNA-lncRNA signature incorporating seven mRNAs and three lncRNAs. Prognostic and predictive accuracy of the signature was tested in the training set of 167 TNBC patients and further validated in an independent validation set of 143 TNBC patients. Results In the training set, we identified 36 mRNAs and 32 lncRNAs which were tumor-specific and significantly associated with patients' RFS. Using the LASSO Cox regression model, an integrated mRNA-lncRNA signature based on seven mRNAs (CCR4, CTSB, ERO1L, HIF1A, IGFR1R, SRD5A1 and TFF1) and three lncRNAs (n381928, n333541 and TCONS_I2_00013109-XLOC_I2_007048) was developed in the training set and subsequently validated in the validation set. Patients were classified to the high-risk (high risk of recurrence) and low-risk (low risk of recurrence) groups according to their scores in the signature. In the training set, multivariate analysis showed that the predicted high-risk group had higher risk of developing recurrent disease within five years of surgery than the low-risk patients (hazard ratio [HR] = 6.12, 95% confidence interval [CI] 2.76-13.56, P<0.001). In the validation set, the predicted high-risk group also had poorer RFS in multivariate analysis (HR = 5.09, 95% CI 1.82-10.96, P<0.001). Furthermore, analyzing the areas under the time-dependent receiver operating curve for five-year RFS, we proved the integrated mRNA-lncRNA signature had better prognostic value than the seven-mRNA-only signature and clinicopathological risk factors in both the training and validation sets. Finally, Cox proportional hazards models were utilized to test the interaction between adjuvant chemotherapy and different risk groups. Patients in the low-risk group had a more favorable response to adjuvant chemotherapy both in the training and validation sets. Conclusion The integrated mRNA-lncRNA signature is a reliable tool for predicting disease recurrence and benefit of adjuvant chemotherapy in TNBC patients. If further validated in larger population, it could facilitate patient counseling and individualize treatment of TNBC. Citation Format: Yizhou Jiang, Yi-Rong Liu, Ke-Da Yu, Xin Hu, Xiao-En Xu, Ling Yao, Zhi-Ming Shao. Prognostic and predictive value of an integrated mRNA-lncRNA signature in triple-negative breast cancer: A comprehensive transcriptome analysis [abstract]. In: Proceedings of the Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2014 Dec 9-13; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2015;75(9 Suppl):Abstract nr P6-08-28.

Abstract 3544: Tumor Suppressor Function of Loc285194 in Breast Cancer

Role of BC040587 As a Predictor of Poor Outcome in Breast Cancer

Low expression of LOC285194 is associated with poor prognosis in colorectal cancer

ZGRF1 is Associated with Poor Prognosis in Triple-Negative Breast Cancer and Promotes Cancer Stemness Based on Bioinformatics.

Association of decreased expression of long non-coding RNA LOC285194 with chemoradiotherapy resistance and poor prognosis in esophageal squamous cell carcinoma

LINC00472 expression is regulated by promoter methylation and associated with disease-free survival in patients with grade 2 breast cancer

Predictive Value of Lncrna LOC100505851 in Breast Cancer in the Neoadjuvant Setting.

Abstract P1-05-08: LINC00926 Interacts with HNRNPC and Suppress Metastasis in Breast Cancer

MiR-5195-3p functions as a tumor suppressor by targeting RHBDD1 in ovarian cancer

OTT_A_222967 10639..10650

Abstract 2251: Tumor Tissue Gene Expression in Association with Survival of Triple-Negative Breast Cancer

Downregulation of LINC01140 is Associated with Adverse Features of Breast Cancer

Bioinformatic analysis of the expression and prognosis of ZNF589 in human breast cancer

Abstract P6-08-28: Prognostic and Predictive Value of an Integrated Mrna-Lncrna Signature in Triple-Negative Breast Cancer: A Comprehensive Transcriptome Analysis

High Expression of Linc00959 Predicts Poor Prognosis in Breast Cancer

Long Non-Coding RNA LOC572558 Inhibits Bladder Cancer Cell Proliferation and Tumor Growth by Regulating the AKT–MDM2–p53 Signaling Axis

Biology of Human Tumors miR-2045 p Inhibits Proliferation and Invasion and Enhances Chemotherapeutic Sensitivity of Colorectal Cancer Cells by Downregulating RAB 22 A

Abstract 1105: Tumor Cells of the Early Metastatic Process Show Up Regulation of Cytokine Genes Involved in Migration of Inflammatory Cells

Abstract A023: lncRNA-protein interactions that predict response to endocrine therapy in HR+ breast cancer

Long Non-Coding RNA Loc554202 Induces Apoptosis in Colorectal Cancer Cells Via the Caspase Cleavage Cascades

Overexpression of FAM234B Predicts Poor Prognosis in Patients with Luminal Breast Cancer.